Take Home Injectable Opioids for Opioid Use Disorder during and after the COVID-19 Pandemic is in urgent need: a case study

Exploring Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment

Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method
study protocol

Public Health Ontario evidence brief on injectable opioid assisted treatment (iOAT)

Investigating opioid preference to inform safe supply services: A cross sectional study. 

Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic–Is an update of legal restrictions warranted?

Evaluation of the Risk Mitigation Guidance in British Columbia: Interim Findings

Injectable Opioid Assisted Treatment (iOAT) cost effectiveness and evidence review by the Canadian Agency for Drugs and Technology in Health (CADTH)

Reducing harm through the development of good preparation practices for the injection of slow release morphine sulphate
capsules:

https://d3n8a8pro7vhmx.cloudfront.net/unitedforsafesupply/pages/35/attachments/original/1582481976/1._Oviedo-Joekes.NEJM.2009.pdf?1582481976

https://d3n8a8pro7vhmx.cloudfront.net/unitedforsafesupply/pages/35/attachments/original/1582481990/4._Bansback_2018.pdf?1582481990